Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

The present invention relates to a chiral spiro phosphine-nitrogen-sulfur (PNS) tridentate ligand, preparation method and application thereof. The PNS tridentate ligand is a compound represented by Formula I or Formula II, their racemates, optical isomers, or catalytically acceptable salts thereof. The ligand has a primary structure skeleton characterized as a chiral spiro indan skeleton structure with a thio group. The chiral spiro phosphine-nitrogen-sulfur tridentate ligand can be synthesized by reacting racemic or optical active compound 7-diary/alkyl phosphine-7-amino-1, 1-spiro-dihydro-indene compound having a spiro-dihydro-indene skeleton as the starting material. The chiral spiro PNS tridentate ligand being complex with transition metal salt can be used in an asymmetric catalytic hydrogenation reaction for catalyzing carbonyl compound. In particular, in asymmetric hydrogenation reaction process, being complex with iridium for catalyzing -alkyl--keto ester can obtain a high catalytic activity (a catalyst amount of 0.0002% mol) and high enantioselectivity (up to 99.9% ee) result. So the present invention has a practical value for industrial and commercial production. ##STR00001##

The present invention relates to: a compound as a ligand in a variety of catalytic organic synthetic reactions; a method for producing the compound; a synthetic intermediate of the compound; and a transition metal complex which has the compound as a ligand. The compound includes a compound represented by the following general formula (1.sup.A): ##STR00001##

Disclosed herein is a dental composition having a polymerization initiator system with an aromatic tertiary phosphine compound. Further disclosed is the use of the aromatic tertiary phospine compound for the preparation of a photocurable dental compositions.

A compound represented by the structure of formula (I):

##STR00001##

The compound is useful as a ligand for ruthenium to form an organometallic complex. The complex may be immobilized on an oxidic support to form an active, heterogeneous catalyst for the hydrogenolysis of amides to form amines and optionally alcohols.

There is provided a method for producing a catalyst liquid containing a Group 6 to 11 transition metal catalyst in which the transition metal catalyst can be prevented from being blackened during storage, the method including performing addition of an alkenyl compound and addition of a phosphorus ligand, and then performing addition of a Group 6 to 11 transition metal catalyst

The present invention relates to the use of novel adducts of general formula (I) TPP.sub.xTPOP.sub.(1-x), wherein TPP is triphenylphosphine, TPOP is triphenylphosphite and x is a real number between 0.05 and 0.9. These novel adducts are useful for the bromination of primary alcohols, in particular for the bromination of primary alcohols.

The present invention includes a molecule, a method of identifying said molecule, and a method of using said molecule to inhibit the interaction of A and Drp1 proteins. The molecules including diethyl (3,4-dihydroxyphenethylamine)(quino-lin-4-yl)methylphosphonate (DDQ); [10-(4,5-dimethoxy2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (MitoQ); 3-Hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxy-benzylidene)-hydrazide (Dynasore); and/or 3-(2,4Dichloro-5-methoxyphenyl)-2,3-dihydro-2-thioxo-4(1H)-quinazolinone/3-(2,4-Dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone (Mdivi-1).

An organic magnesium phosphide expressed by Formula (1) below and an organic magnesium phosphide complex expressed by Formula (9) below are provided, and a manufacturing method of organic phosphorus compound is characterized in that the above compounds used as a reagent is reacted with an electrophile: ##STR00001##
wherein R.sup.1 and R.sup.2 are each independently an aliphatic group, heteroaliphatic group, alicyclic group, or heterocyclic group, and X is chlorine, bromine, or iodine, ##STR00002##
wherein R.sup.3 and R.sup.4 are each independently an aliphatic group, heteroaliphatic group, aromatic group, alicyclic group, or heterocyclic group, and X and Y are each independently chlorine, bromine, or iodine.

Disclosed are quantum dots and quantum dot articles stabilized by a stabilizing agent of the formula:

##STR00001##